Cells of the human respiratory tract support the replication of pathogenic Old World orthohantavirus Puumala

Stefan Hägele, Christian Nusshag, Alexander Müller, Alexandra Baumann, Martin Zeier and Ellen Krautkrämer*

Abstract

Background: Transmission of all known pathogenic orthohantaviruses (family Hantaviridae) usually occurs via inhalation of aerosols contaminated with viral particles derived from infected rodents and organ manifestation of infections is characterized by lung and kidney involvement. Orthohantaviruses found in Eurasia cause hemorrhagic fever with renal syndrome (HFRS) and New World orthohantaviruses cause hantavirus cardiopulmonary syndrome (HCPS). However, cases of infection with Old World orthohantaviruses with severe pulmonary manifestations have also been observed. Therefore, human airway cells may represent initial targets for orthohantavirus infection and may also play a role in the pathogenesis of infections with Eurasian orthohantaviruses.

Methods: We analyzed the permissiveness of primary endothelial cells of the human pulmonary microvasculature and of primary human epithelial cells derived from bronchi, bronchioles and alveoli for Old World orthohantavirus Puumala virus (PUUV) in vitro. In addition, we examined the expression of orthohantaviral receptors in these cell types. To minimize donor-specific effects, cells from two different donors were tested for each cell type.

Results: Productive infection with PUUV was observed for endothelial cells of the microvasculature and for the three tested epithelial cell types derived from different sites of the respiratory tract. Interestingly, infection and particle release were also detected in bronchial and bronchiolar epithelial cells although expression of the orthohantaviral receptor integrin β3 was not detectable in these cell types. In addition, replication kinetics and viral release demonstrate enormous donor-specific variations.

Conclusions: The human respiratory epithelium is among the first targets of orthohantaviral infection and may contribute to virus replication, dissemination and pathogenesis of HFRS-causing orthohantaviruses. Differences in initial pulmonary infection due to donor-specific factors may play a role in the observed broad variance of severity and symptoms of orthohantavirus disease in patients. The absence of detectable levels of integrin αVβ3 surface expression on bronchial and small airway epithelial cells indicates an alternate mode of orthohantaviral entry in these cells that is independent from integrin β3.

Keywords: Orthohantavirus, Lung, Endothelium, Epithelium, Puumala virus, Integrin, Receptor

Introduction

Infections with orthohantaviruses, formerly named hantaviruses, cause two diseases: hemorrhagic fever with renal syndrome (HFRS) by Old World orthohantaviruses found in Eurasia and hantavirus cardiopulmonary syndrome (HCPS) by New World orthohantaviruses of the American continents [1, 2]. HFRS is characterized...
by acute kidney injury, whereas the cardio-pulmonary involvement predominates in HCPS [3, 4]. However, the reasons for the virus-specific organ manifestations in both diseases despite transmission of all orthohantaviruses by inhalation are not known.

The clinical picture of infectious diseases depends on the tropism of the invading pathogen. Infection of target cells contributes to the clinical symptoms and is responsible for the dysfunction or even failure of the affected organ. Histopathological analysis of autopsy samples derived from HCPS patients infected with the New World orthohantavirus Sin Nombre (SNV) demonstrates that viral antigen was found in a number of organs such as lung, kidney, spleen, intestine, or lymph nodes [5]. The presence of viral antigen in different organs was also described for HFRS patients. In addition to infected cells in the kidney, viral antigen was also detected in the lung, intestine, in cells from bronchoalveolar lavage, in endothelial cells of the parotid gland, and RNA of Old World orthohantavirus Puumala virus (PUUV) was found in saliva [6–12]. Several cell culture studies in the African Green Monkey cell line Vero E6 and primary endothelial cells of the human umbilical vein (HUVEC) identified integrin β3 as entry receptor for pathogenic orthohantaviruses such as SNV. New York virus, Hantaan virus (HTNV), PUUV, Seoul virus, and Dobrava-Belgrade virus (DOBV); in addition, CD55 was described as co-receptor for entry of HTNV, PUUV, and DOBV [13–17]. Receptor expression and usage determines the tropism of viruses. However, the expression and the role of integrin β3 and CD55 for the entry in cells of orthohantaviral target organs have not been analyzed in detail so far.

Detection of orthohantaviral genomes and antigen in endothelial and epithelial cells of various tissues indicates a broad range of organ tropism and may explain the extrarenal manifestations observed in Old World orthohantavirus infection. HFRS-cases complicated by acute respiratory distress syndrome caused by HTNV are described in China and cases with severe respiratory symptoms are reported in the context of PUUV infections in Europe [9, 18–22]. The underlying mechanisms for the renal-pulmonary presentation of these infections caused by HTNV and PUUV are not completely understood. Direct virus-induced and immune response mediated effects as well as multiorgan dysfunction may contribute to the observed respiratory symptoms [3]. Tissue-specific damage is often caused by immune cell-mediated cytotoxicity that takes place at the site of viral infection to eliminate infected cells. As shown for New World orthohantaviruses, patients with PUUV infection also demonstrate pulmonary pathogenesis due to local cellular immune response in the airways [20, 23–26].

Orthohantaviruses are transmitted via inhalation of aerosols containing virions excreted from infected host animals. Therefore, cells of the respiratory tract may represent initial targets for infection by inhaled particles. However, replication of Old World orthohantaviruses in lung cells is not investigated in detail so far. To analyze if pulmonary cells may serve as primary entry site in human infections with Old World orthohantavirus PUUV, we examined receptor expression and infection of human primary cells derived from different parts of the respiratory tract.

Material and methods

Cells

Primary human pulmonary microvascular endothelial cells (HPMEC), human small airway epithelial cells (HSAEpC), and human bronchial epithelial cells (HBEpC) were obtained from PromoCell (Germany). Human pulmonary alveolar epithelial cells (HPAEPiC) were purchased from ScienCell (USA). The cells were maintained in Endothelial Cell Growth Medium MV2, Small Airway Epithelial Growth Medium, Airway Epithelial Growth Medium (all from PromoCell), and Alveolar Epithelial Cell Medium (ScienCell). Only cells from passages two to six were used. Cells derived from two different donors were analyzed for every cell type. Each individual is indicated by a three digit numeral identity code: HPMEC: donor #011 and #016; HBEpC: donor #359 and #404; HSAEpC: donor #210 und #306; HPAEPiC: donor #144 and #167. Cells were seeded at 10,000 cells/cm². Vero E6 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum.

Virus infection and quantification of infection

Puumala virus (PUUV) strain Vranica isolated from bank vole [27, 28] was propagated and titrated on Vero E6 cells. For infection, virus inoculum (4.6 × 10⁵ IU/ml) was added at a multiplicity of infection (MOI) of 1 to primary pulmonary cells. After incubation for two hours at 37 °C, unbound virus was removed by triple washing with the appropriate medium. Infection was analyzed by immunofluorescence and Western blot analysis for orthohantaviral nucleocapsid protein (N protein). Infection kinetics were monitored by immunofluorescence staining of N protein and quantification of the percentage of positive cells. Experiments were performed in triplicates for each donor. Representative figures of day 6 post infection were shown in Figs. 1, 2 and 3.

Quantification of viral release

To quantify the release of infectious particles from pulmonary cells, a first round of infection assay in Vero E6...
Number of initially infected cells was quantified early after inoculation (48 h post inoculation) during the first replication cycle to avoid an overestimation of viral titers by second rounds of infection.

Cell-free supernatants from infected human pulmonary cells were collected on day two, four and six after infection and 10 µl of supernatant were added to Vero E6 cells for two hours. Inoculum was removed by a triple washing with medium. After 48 h, the total number of initially infected Vero E6 cells was quantified by immunofluorescence staining of PUUV N protein. The total number of infected Vero E6 cells corresponds to the number of infectious units (IU) in 10 µl. Titers were expressed as IU per ml supernatant. Experiments were performed in triplicates. Representative images of Vero E6 monolayers inoculated with supernatant of day 6 after infection were taken and shown in Figs. 1 and 2. All PUUV-related experiments were performed in a biosafety level 2 (BSL-2) setting.

**Immunofluorescence and Western blot**

For immunofluorescence, cells grown on coverslips were fixed, permeabilized and stained with primary and appropriate fluorescently-labelled secondary antibodies. The following antibodies were used: mouse anti-CD31 (endothelial marker) (Dako), mouse anti-cytokeratin 18 (epithelial marker) (Millipore), mouse anti-PUUV nucleocapsid protein (Progen), and mouse anti-integrin αVβ3, clone LM609 (orthohantaviral receptor) (Millipore). Cell nuclei were stained with Hoechst 33342 (Invitrogen). Images were taken using an AxioCam 506 camera attached to an Axio Observer.D1 microscope (Zeiss). For
Western blot analysis, the following primary antibodies were used: rabbit anti-PUUV N protein, rabbit anti-integrin β3 (orthohantaviral receptor) (Santa Cruz) and mouse anti-α-tubulin (Sigma). Equal loading was verified by the detection of tubulin on the same membrane. Detection was performed by using near infrared fluorescent dye (IRDye)-conjugated secondary antibodies and an Odyssey infrared imaging system (Li-Cor Biosciences).

Flow cytometry analysis of orthohantaviral entry receptors
Cells were washed, scraped and stained with allophycocyanin (APC)-conjugated mouse anti-CD55 (orthohantaviral receptor) antibody (BD Pharmingen) and phycoerythrin (PE)-conjugated mouse anti-integrin αvβ3 (orthohantaviral receptor) antibody, clone LM609 (Millipore) or the corresponding isotype control. After one hour of incubation on ice, cells were washed and analyzed by flow cytometry with FACSCalibur (BD)

**Fig. 2** Infection of primary human pulmonary epithelial cells with PUUV. **A** Detection of marker proteins CD31, cytokeratin 18 and orthohantaviral receptor integrin αvβ3 (scale bar: 100 µm). **B** HBEpCs, HSAEpCs, and HPAEpiCs were infected with PUUV. Infection and release were monitored by detection of N protein via immunofluorescence and via Western blot analysis of lysates and cell-free supernatants (SN) on day 6 post infection (scale bar: 100 µm). **C** Vero E6 cells were incubated with cell-free supernatants of uninfected or PUUV-infected pulmonary epithelial cells (6 dpi) and stained for N protein after 48 h post inoculation (scale bar: 100 µm).
Pharmingen). Flow cytometry analysis of cell viability was monitored by using Via-Probe™ Cell Viability Solution (BD Pharmingen) according to manufacturer’s instructions.

Statistical analysis
Data were analyzed using Prism 5.0 (GraphPad Software Inc.). Values of two groups were compared using two-tailed Student’s t-test. \( P \) values of <0.05 were considered significant. \( *P<0.05; **P<0.005; ***P<0.0005; ****P<0.0001; ns: not significant. \)

Results
Infection of human primary pulmonary cells with PUUV
We examined human pulmonary microvascular endothelial cells (HPMEC) for their permissiveness and susceptibility to PUUV (Fig. 1). The endothelial identity of HPMEC was validated by the presence of the endothelial marker protein CD31 and the absence of the epithelial marker protein cytokeratin 18 (CK18). HPMECs were positive for CD31 and no expression of CK18 was detectable. Expression of orthohantaviral receptor integrin \( \alpha_V\beta_3 \) was observed by immunofluorescence (Fig. 1A).

Inoculation of HPMECs with PUUV resulted in productive infection as shown by the detection of N protein in cells, lysate and supernatant (SN) (Fig. 1B). The release of infectious particles was demonstrated by reinfection of Vero E6 cells with cell-free supernatant derived from infected lung endothelial cells (Fig. 1C).

In a next step, we analyzed the infection of pulmonary epithelial cells of different parts of the respiratory tract, which represents a primary target epithelium for orthohantaviruses. HBEpCs isolated from human bronchi, HSAEpCs originating from 1 mm bronchiole area, and HPAEpiCs derived from alveoli were examined for marker proteins, receptor expression and permissiveness for PUUV infection (Fig. 2). Immunofluorescence analysis revealed that all epithelial cells were positive for the expression of the epithelial marker CK18 and negative for the endothelial marker CD31. HBEpCs and HSAEpCs, expression of the integrin \( \alpha_V\beta_3 \) heterodimer was not detectable. In contrast, expression of integrin \( \alpha_V\beta_3 \) was present in HPAEpiCs (Fig. 2A).

Detection of PUUV N protein in cells and lysates six days after inoculation with PUUV demonstrated that all three pulmonary epithelial cell types were infected with PUUV (Fig. 2B). Infectious particles were released from pulmonary epithelial cells as shown by the detection of N protein in cell-free supernatants together with the reinfection of Vero E6 cells (Fig. 2B, C).

Infection of pulmonary cells derived from second donors
To identify possible donor-specific effects in primary human pulmonary cells, cells of second donors were subjected to PUUV infection (Fig. 3). The endothelial and epithelial phenotype of all cell types was demonstrated by immunofluorescence staining for the endothelial marker CD31 and the epithelial marker CK18 (Fig. 3A). As observed for the first donors, all tested pulmonary cell types were permissive for infection with PUUV (Fig. 3B). The results of the receptor analysis in the second donors correspond to the observations made in the cells of the previous donors: expression of integrin \( \alpha_V\beta_3 \) was not detectable in HBEpCs and in HSAEpCs and for HPMECs and HPAEpiCs, the expression of orthohantaviral receptor integrin \( \alpha_V\beta_3 \) was confirmed in cells derived from second donors (Fig. 3A).

Together, our results demonstrate the permissiveness of human endothelial and epithelial pulmonary cells and the absence of detectable levels of integrin \( \alpha_V\beta_3 \) in cells derived from bronchi and bronchioles.

Receptor expression in human primary pulmonary cells
To analyze the receptor expression in more detail, we examined surface expression of entry receptors by flow cytometric analysis (Fig. 4A). We stained pulmonary cells for integrin \( \alpha_V\beta_3 \) and CD55, a co-receptor of orthohantaviral entry [15]. All pulmonary cells express CD55. Surface expression of integrin \( \alpha_V\beta_3 \) was absent from HBEpCs and HSAEpCs and was present in HPMECs and HPAEpiCs. Integrins are heterodimeric receptors composed of \( \alpha \) and \( \beta \) subunits and despite expression of \( \beta \) subunits, assembly and surface expression may be influenced by rate-limiting \( \alpha \) subunits [29]. Therefore, we tested the expression of integrin \( \beta_3 \) subunit in pulmonary cells by Western blot analysis (Fig. 4B). Integrin \( \beta_3 \) subunit expression was not detectable in HBEpCs and HSAEpCs by Western blot. In contrast, integrin \( \beta_3 \) subunit was observed in HPMECs and HPAEpiCs.
Fig. 3 (See legend on previous page.)
Fig. 4 Receptor expression in human primary pulmonary cells from two donors. A Surface expression of integrin αβ3 and CD55 on human pulmonary cells was analyzed by flow cytometry. B Detection of integrin β3 subunit expression in lysates from human pulmonary cells by Western blot.
We showed the absence of detectable levels of integrin αVβ3 surface expression as well as the lack of integrin β3 subunit expression in HBEpCs and HPAEpiCs. The results concerning absence and presence of receptor expression are consistent between donors.

Replication kinetics of PUUV in human primary pulmonary cells
We directly compared kinetics of PUUV replication between different pulmonary cell types and between the two donors (Fig. 5 and Table 1). Number of infected cells and release of infectious particles were monitored over time by immunofluorescence-based assays. Western blot analysis of lysates and supernatants does not allow quantification due to possible cell type-specific differences between levels of N protein expression in infected cells and N protein detected in supernatants may be derived from defective non-infectious particles. The percentage of infected cells after initial infection increased in all cell types and donors and infectious particles were released over time. However, replication kinetics differ between pulmonary cell types. HPMECs, HSAEpcCs, and HPAEpiCs demonstrated an increase of infected cells between day two and four after inoculation, whereas viral spread in HBEpCs started not before day four after infection. The percentage of infected cells reached its maximum at 6 dpi for HPMECs, HBEpCs, HSAEpcCs of both donors. In contrast, the levels of infected HPAEpiCs peaked at 4 dpi and decreased at 6 dpi. The time course of replication kinetics is similar between donors of the same cell type, but donors demonstrate enormous variations in the percentage of infected cells. On day six post infection, 1.5- to threefold differences in the percentage of infected cells were observed between donors (Table 1). Analysis of titers of infectious particles revealed also significant donor-specific variation in viral release (Fig. 5B and Table 1). However, the amount of virion production is not related to the amount of infected pulmonary cells. Production of infectious particles may be reduced due to antiviral mechanisms of infected cells or by the
production of defective non-infectious particles [30]. Nevertheless, number of infected cells may increase despite a decrease of viral release if infectious particles are present in excess compared to the number of permissive cells.

In addition, there is apparently no relationship between the presence/absence of integrin expression and permissiveness of primary cells. Lowest initial infection rates were observed in HPAEpiCs #167 (9.3% ± 1.8%) that express integrin αVβ3 and in HSAEpCs #210 (9.6% ± 1.9%) that have no detectable integrin αVβ3 expression (Table 1). In addition, highest initial infection rates were also observed in cells with (HPMEC #011, 34.6 ± 9.8%) and without (HSAEpCs #306, 47.1% ± 2.8%) integrin αVβ3 expression. Together, the permissiveness of pulmonary cells and donors varies enormously and does not depend on the expression of integrin αVβ3.

### Discussion

The respiratory tract is the first region of contact for many pathogens. The ability of the pathogen to enter and to replicate in certain pulmonary cell types may influence the clinical picture and disease severity as shown for influenza virus and coronaviruses [31, 32]. However, the knowledge about initial target cells, replication sites and mode of dissemination to more distant target organs in human infection is often incomplete. By transmission via inhalation, pulmonary cells also represent possible target cells for human orthohantavirus infection. In chronically orthohantavirus-infected host rodents, lung tissue reveals the highest viral load [33]. Infected endothelial and epithelial cells of the human respiratory tract were detected in patients with New and Old World orthohantavirus infection [5, 34–36].

Cell culture infection studies in pulmonary cells also exist for orthohantaviruses. In vitro infection of human lung microvascular endothelial cells with SNV or HTNV in a 3D human lung tissue model results in the induction of chemokine expression and may contribute to an immune-mediated increase in vascular permeability [37]. Studies in cell culture models revealed the productive infection of hamster tracheal epithelial cells by New World orthohantavirus Andes virus (ANDV) without visible cellular damage [38]. The authors assume that replication in pulmonary cells may contribute to virus dissemination in the early steps of orthohantavirus infection. In vitro cell culture studies with Old World orthohantaviruses were often performed in the human pulmonary epithelial cell line A549 [39–42]. Interestingly, pathogenic orthohantaviruses replicate more efficiently in A549 cells than non-pathogenic species and infections with three subtypes of the species Dobrava-Belgrade orthohantavirus result in changes in the gene expression profile that correspond to the virulence of the respective virus subtype [39]. These results reflect the importance and suitability of human pulmonary epithelial cells as infection model for orthohantaviral pathogenesis. The infection of specific cell types in vitro is a useful tool to examine cell tropism, replication cycle and direct functional consequences, especially if relevant cells from human target organs were used [37, 43]. Of course, disease-specific effects may be caused by the cross-talk of cell types in a tissue-specific environment and by the activation of immune cells. These mechanisms cannot be properly analyzed in cell culture or tissue models. However, the detailed study of pathogenesis is still hampered by the lack of an adequate small animal model for Old World orthohantavirus infection [44]. Therefore, orthohantavirus research still depends on suitable human in vitro cell culture models to analyze replication cycle and pathogenesis.

Our work with human primary pulmonary endothelial and epithelial cells demonstrates the permissiveness

### Table 1: PUUV infection and release of human primary pulmonary cells

| Cell type          | % infected cells (mean ± SD) | Infectious units/ml (mean ± SD) |
|--------------------|-------------------------------|--------------------------------|
|                    | 2 dpi 4 dpi 6 dpi             | SN 2 dpi  SN 4 dpi  SN 6 dpi   |
| HPMEC #011         | 34.6±9.8 63.9±5.9 82.8±3.6    | 1.7 ± 10^7 ± 3.8 ± 10^4 6.3 ± 10^7 ± 1.8 ± 10^4 1.0 ± 10^7 ± 2.2 ± 10^4 |
| HPMEC #016         | 18.5±1.8 33.0±2.9 53.7±2.7    | 0.4 ± 10^7 ± 0.1 ± 10^4 1.0 ± 10^7 ± 0.2 ± 10^4 2.4 ± 10^7 ± 0.4 ± 10^4 |
| HBEpc #359         | 18.3±3.1 12.2±1.1 60.4±4.2    | 8.8 ± 10^7 ± 8.0 ± 10^3 2.8 ± 10^7 ± 2.1 ± 10^3 1.9 ± 10^7 ± 2.1 ± 10^3 |
| HBEpc #404         | 13.7±3.8 160±1.6 290±2.1      | 4.8 ± 10^7 ± 4.1 ± 10^2 4.2 ± 10^7 ± 2.1 ± 10^3 8.9 ± 10^7 ± 2.7 ± 10^3 |
| HSAEpC #210        | 9.6±1.9 241±1.1 274±5.9       | 3.2 ± 10^7 ± 1.8 ± 10^4 4.2 ± 10^7 ± 8.2 ± 10^4 4.2 ± 10^7 ± 5.9 ± 10^3 |
| HSAEpC #306        | 47.1±2.8 668±0.3 85.2±0.4     | 6.1 ± 10^7 ± 1.4 ± 10^4 2.3 ± 10^7 ± 2.2 ± 10^4 5.4 ± 10^7 ± 1.6 ± 10^3 |
| HPAEpiC #144       | 16.2±3.2 517±5.5 45.4±1.3     | 1.5 ± 10^7 ± 1.2 ± 10^5 8.8 ± 10^7 ± 6.7 ± 10^5 3.8 ± 10^7 ± 1.4 ± 10^3 |
| HPAEpiC #167       | 9.3±1.8 90.3±1.6 77.5±0.4     | 9.1 ± 10^7 ± 5.9 ± 10^5 5.3 ± 10^7 ± 4.0 ± 10^5 7.3 ± 10^7 ± 3.7 ± 10^5 |

*SD* standard deviation, *SN* supernatant, *dpi* days post infection
of human cells within different parts of the respiratory tract for the Old World orthohantavirus PUUV. Epithelial and endothelial cells of the lung support orthohantaviral replication as observed for the infection of different cells from the kidney, which represent epithelial (tubular epithelial cells, podocytes) and endothelial (glomerular endothelial cells) cell types [7, 45, 46]. Interestingly, productive infection of bronchial and small airway epithelial cells occurred without detectable expression of integrin αβ3 or integrin β3 subunit. The absence of integrin β3 expression in normal human bronchial epithelium was also reported in several studies analyzing tissue samples or primary human bronchial epithelial cells [47–49]. Integrin β3 was described to serve as entry receptor for pathogenic orthohantaviruses by cell culture studies [13, 14]. In addition, there is a growing list of co-factors and receptors that have been identified in vitro studies: CD55, gC1qR, protocadherin-1 or TIM-1 (T-cell immunoglobulin and mucin domain 1) were described to play a role in the entry of various orthohantavirus species in different cell culture models [15–17, 50–53]. Infection of several human cell types and of a PUUV host species cell line without integrin β3 expression was also observed [54–56]. Torriani et al. describe that orthohantavirial entry in human airway epithelial cells depends on macropinocytosis and identified differences between the New World orthohantavirus ANDV and the Old World orthohantavirus HTNV [57]. As a conclusion from these in vitro results, the entry of orthohantaviruses seems to be specific for different virus species and may also vary between cell types.

The replication analysis revealed differences in the kinetics of PUUV infection and release between donors. Donor-specific variation in permissiveness was also described for the infection of human airway epithelial cells with H1N1 Influenza virus and Nipah virus [58, 59]. The susceptibility and permissiveness for viral infection is influenced by host cell factors. Cellular antiviral response may account for differences in infection kinetics and may influence the clinical course and disease severity of viral infections. Differences in the individual immune response in patients infected with PUUV were observed [60, 61]. Behavioral factors (e.g. smoking) and genetic determinants such as HLA alleles or cytokine polymorphisms may contribute to the observed variation of immune response in infected individuals [62–67].

Based on the detection of orthohantaviral antigen in lungs of infected patients and the results from in vitro cell culture studies, pulmonary cells may represent target cells of orthohantavirus infection. The release of infectious particles indicates a possible viral spread in lung tissue. Nevertheless, a person-to-person transmission is not described for orthohantaviruses with the exception of ANDV [68–70]. The reasons for this remain unclear and were also discussed in the work of Pettersson et al., which describes the detection of PUUV RNA in the saliva of patients and a possible inhibition of virus transmission by salivary components [10].

In summary, the replication of orthohantaviruses in pulmonary epithelial cells may play a pivotal role in the initial phase of transmission, virus dissemination, and pathogenesis of pulmonary symptoms in orthohantavirus disease. Differences between donors and orthohantavirus species in pulmonary infection should be investigated in more detail in future work.

**Conclusions**
Orthohantaviruses are transmitted via inhalation of contaminated aerosols and infections are characterized by specific manifestations in kidney and/or lung. As shown for renal cells, pulmonary cells may represent target cells of PUUV infection. The infection of bronchial and bronchiolar cells occurs in the absence of detectable integrin β3 expression indicating an alternate mode of entry in pulmonary cells. Patient-specific differences in the initial pulmonary replication as observed in vitro for cells from different donors may contribute to the severity of the clinical course. Therefore, the detailed analysis of orthohantaviral replication cycle in pulmonary cells is of special interest and will provide helpful insights in the mechanisms of orthohantaviral initial infection and its impact on pathogenesis.

**Abbreviations**
ANDV: Andes virus; dpi: Days post infection; DOBV: Dobrava-Belgrade virus; HBEpC: Human bronchial epithelial cells; HCS: Hantaviral cardiopulmonary syndrome; HFRS: Hemorrhagic fever with renal syndrome; HPAEpiC: Human pulmonary alveolar epithelial cells; HPMEC: Human pulmonary microvascular endothelial cells; HSAEpC: Human small airway epithelial cells; HTNV: Hantaan virus; IU: Infectious units; MOI: Multiplicity of infection; N protein: Nucleocapsid protein; PUUV: Puumala virus; SD: Standard deviation; SN: Supernatant; SNV: Sin Nombre virus.

**Acknowledgements**
We thank Josephine Uhrig and Vanessa Bollinger for technical assistance.

**Authors’ contributions**
EK designed the experiments and wrote the manuscript. SH contributed to the manuscript and performed experiments. AM, AB performed experiments. CN, MZ contributed to the analysis of the results and to the final version of the manuscript. All authors read and approved the final manuscript.

**Funding**
Open Access funding enabled and organized by Projekt DEAL.

**Availability of data and materials**
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 28 January 2021   Accepted: 9 August 2021

Published online: 17 August 2021

References

1. Vahren A, Strandin T, Heipojoki J, Sironen T, Henntonen H, Makela S, Mustonen J. Uncovering the mysteries of hantavirus infection. Nat Rev Microbiol. 2013;11:539–50.

2. Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010;23:412–41.

3. Manigold T, Vial P. Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology. Swiss Med Wkly. 2014;144:w13937.

4. Krautkrämer E, Krüger DH, Zeier M. Recent outbreaks of hantavirus infections in Germany and in the United States. Kidney Int. 2012;82:1243–5.

5. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, Federsen RM, Zimmuth RE, Miller KL, Khan AS, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol. 1995;146:552–79.

6. Kim S, Kang ET, Kim YG, Han JS, Lee JS, Kim YI, Hall WC, Dalrymple JM, Peters CJ. Localization of Hantaan viral envelope glycoproteins by monoclonal antibodies in renal tissues from patients with Korean hemorrhagic fever. Am J Pathol. 1993;100:398–403.

7. Krautkrämer E, Grouls S, Stein N, Reiser J, Zeier M. Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembly of cell-to-cell contacts. J Virol. 2011;85:8911–23.

8. Latus J, Tenner-Racz K, Racz P, Kitterer D, Cadar D, Ott G, Alscher MD, Schmidt-Chanasit J, Braun N. Detection of Puumala hantavirus antigen in human intestine during acute hantavirus infection. PLoS ONE. 2014;9:e98397.

9. Giuzzi M, Delaere B, Weynand B, Clement J, Maes P, Souza RL, Aquino VH, Saggioro FP, Figueiredo LT. Hantavirus cardiopulmonary syndrome: immune response and pathogenesis. Microbes Infect. 2006;8:2324–30.

10. Terajima M, Hayasaka D, Maeda K, Ennis FA. Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: do CDB+ T cells trigger capillary leakage in viral hemorrhagic fevers? Immunol Lett. 2007;113:117–20.

11. Reip A, Haring B, Sibold C, Stohwasser R, Bautz EK, Darai G, Meisel H, Sironen T, Sane J, Lokki ML, Meri S, Andersson LC, Hautala T, Kauma H, Vuurinneren S, Rasmussen J, Evanson RM, et al. Fatal Puumala hantavirus disease: involvement of complement activation and vascular leakage in the pathobiology. Open Forum Infect Dis. 2017;4:ofx229.

12. Borges AA, Campos GM, Moreli ML, Souza RL, Aquino VH, Saggioro FP, Figueiredo LT. Hantavirus cardiopulmonary syndrome: immune response and pathogenesis. Microbes Infect. 2006;8:2324–30.

13. Scholz S, Baharom F, Rankin G, Maleki KT, Gupta S, Vangetti S, Pourazar J, Dicacciatti A, Heijer J, Bottai M, et al. Human hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in peripheral blood and airways. PLoS Pathog. 2017;13:e1006462.

14. Terajima M, Hayasaka D, Maeda K, Ennis FA. Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: do CDB+ T cells trigger capillary leakage in viral hemorrhagic fevers? Immunol Lett. 2007;113:117–20.

15. Reip A, Haring B, Sibold C, Stohwasser R, Bautz EK, Darai G, Meisel H, Sironen T, Sane J, Lokki ML, Meri S, Andersson LC, Hautala T, Kauma H, Vuurinneren S, Rasmussen J, Evanson RM, et al. Fatal Puumala hantavirus disease: involvement of complement activation and vascular leakage in the pathobiology. Open Forum Infect Dis. 2017;4:ofx229.

16. Garanina E, Martynova E, Davidyuk Y, Kabwe E, Ivanov K, Titova A, Markevicha MN, Zhuravelva M, Cherepnev G, Shahirova VG, et al. Cytokine storm combined with humoral immune response defect in fatal hemorrhagic fever with renal syndrome case, Tatarstan, Russia. Viruses. 2019;11:601.

17. Chan MC, Chan RW, Yu WC, Ho CC, Yuen KM, Fong JH, Tang LL, Lai WW, Lo AC, Chui WH, et al. Tropism and innate host responses of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of human conjunctiva and respiratory tract. Am J Pathol. 2010;176:1826–40.

18. Sungrak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, Talavera-Lopez C, Maatz H, Discacciati A, Hoijer J, et al. The pathobiology. Open Forum Infect Dis. 2013;3:2:1341–5.

19. Pettersson L, Rasmussen J, Andresson C, Ahlm C, Evander M. Hantavirus-specific IgA in saliva and viral antigen in the parotid gland in patients with hemorrhagic fever with renal syndrome. J Med Virol. 2011;83:864–70.

20. Pettersson L, Klangstrom J, Hardestam J, Lundkvist A, Ahlm C, Evander M. Hantavirus RNA in saliva from patients with hemorrhagic fever with renal syndrome. Emerg Infect Dis. 2008;14:406–11.

21. Rasmussen J, Andresson C, Normann E, Haney M, Evander M, Ahlm C. Time to revise the paradigm of hantavirus syndromes? Hantavirus pulmonary syndrome caused by European hantaviruses. Eur J Clin Microbiol Infect Dis. 2011;30:850–9.

22. Gavrillovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. Beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA. 1998;95:7074–9.

23. Gavrillovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol. 1999;73:3951–9.

24. Krautkrämer E, Zeier M. Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55). J Virol. 2008;82:4257–64.

25. Popugaeva E, Witkowski PT, Schlegel M, Ullrich RG, Auste B, Rang A, Krüger DH, Klempl B. Doivara-Belgrade hantavirus from Germany shows receptor usage and innate immunity induction consistent with the pathogenicity of the virus in humans. PLoS ONE. 2012;7:e35587.

26. Klempa B, Witkowski PT, Popugaeva E, Auste B, Kiovogui L, Fichert-Calvet E, Strecker T, Ter Meulen J, Krüger DH. Sangassou virus, the first hantavirus isolate from Africa, displays distinct genetic and functional properties in the group of Murinae-associated hantaviruses. J Virol. 2012;86:3819–27.

27. Tu H, Li J, Jiang Y, Wu J, Zhang Y, Wang J, Wang P, Bai X. Clinical study of critical patients with hemorrhagic fever with renal syndrome complicated by acute respiratory distress syndrome. PLoS ONE. 2014;9:e89740.

28. Linderholm M, Sandström T, Rinnstrom O, Groth S, Blomberg A, Tarnvik A. Impaired pulmonary function in patients with hemorrhagic fever with renal syndrome. Clin Infect Dis. 1997;25:1084–9.

29. Rasmussen J, Pourazar J, Linderholm M, Sandström T, Blomberg A, Ahlm C. Presence of activated airway T lymphocytes in human puumala hantavirus disease. Chest. 2011;139:715–22.

30. Vollmar P, Lubnow M, Simon M, Muller T, Bergler T, Alos P, Thoma BR, Essbauer S. Hantavirus cardiopulmonary syndrome due to Puumula virus in Germany. J Clin Virol. 2016;84:42–7.

31. Sironen T, Sane J, Lokki ML, Meri S, Andersson LC, Hautala T, Kauma H, Vuurinnen S, Rasmussen J, Evander M, et al. Fatal Puumala hantavirus disease: involvement of complement activation and vascular leakage in the pathobiology. Open Forum Infect Dis. 2017;4:ofx229.

32. Borges AA, Campos GM, Moreli ML, Souza RL, Aquino VH, Saggioro FP, Figueiredo LT. Hantavirus cardiopulmonary syndrome: immune response and pathogenesis. Microbes Infect. 2006;8:2324–30.

33. Terajima M, Hayasaka D, Maeda K, Ennis FA. Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: do CDB+ T cells trigger capillary leakage in viral hemorrhagic fevers? Immunol Lett. 2007;113:117–20.

34. Reip A, Haring B, Sibold C, Stohwasser R, Bautz EK, Darai G, Meisel H, Sironen T, Sane J, Lokki ML, Meri S, Andersson LC, Hautala T, Kauma H, Vuurinnen S, Rasmussen J, Evanson RM, et al. Fatal Puumala hantavirus disease: involvement of complement activation and vascular leakage in the pathobiology. Open Forum Infect Dis. 2017;4:ofx229.
36. Pizarro E, Navarrete M, Méndez C, Zaror L, Mansilla C, Tapia M, Carrasco C, Salazar P, Murua R, Padula P, et al. Immunocytochemical and ultrastructural evidence supporting that Andes Hantavirus (ANDV) is transmitted person-to-person through the respiratory and/or salivary pathways. Front Microbiol. 2019;10:2902.

37. Sundstrom KB, Nguyen Hoang AT, Gupta S, Ahlm C, Svensson M, Klingstrom J. Andes Hantavirus-Infection of a 3D Human Lung Tissue Model Reveals a Late Peak in Progeny Virus Production Followed by Increased Levels of Proinflammatory Cytokines and VEGF-A. PLoS ONE. 2016;11:e0149352.

38. Rowe RK, Pelozz A. Bidirectional virus secretion and nonciliated cell tropism following Andes virus infection of primary airway epithelial cell cultures. J Virol. 2006;80:1087–97.

39. Witkowski PT, Bourquain D, Bankov K, Auste B, Dabrowski PW, Nitsche A, Krüger DH, Schaade L. Infection of human airway epithelial cells by different subtypes of Dobrava-Belgrade virus reveals gene expression patterns corresponding to their virulence potential. Virology. 2016;499:189–201.

40. Stoltz M, Klingstrom J. Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda 1 (interleukin-29) in response to Hantaan virus infection. J Virol. 2010;84:9140–8.

41. Lee MH, Lalwani P, Raftery MJ, Matthaei M, Lutteke N, Kirsanos V, Binder M, Ulrich RG, Giese T, Wolff T, et al. RNA helicase retroin: acidic-inducible gene 1 as a sensor of a Hantaan virus replication. J Gen Virol. 2011;92:2191–200.

42. Shim SH, Park MS, Moon S, Park KS, Song JW, Song KJ, Baek LJ. Comparison of innate immune responses to pathogenic and putative non-pathogenic hantaviruses in vitro. Virus Res. 2011;160:367–73.

43. Häggle S, Müller A, Nussbach C, Reiser J, Zeier M, Krautkrämer E. Virus- and cell type-specific effects in orthohantavirus infection. Virus Res. 2019;260:102–13.

44. Golden JW, Hammerbeck CD, Mucker RL, Brocato RL. Animal models for the study of Rodent-Borne hemorrhagic fever viruses: arenaviruses and hantaviruses. Biomed Res Int. 2015;2015:793257.

45. Bourquain D, Bodenstein C, Schuerer S, Schaade L. Puumala and Tula Virus differ in replication kinetics and innate immune stimulation in human endothelial cells and macrophages. Viruses. 2019;11:855.

46. Temponi M, Vapalahti O, Holthofer H, Brummer-Korvenkontio M, Vaheri A, Lankinen H. Susceptibility of human cells to Puumala virus infection. J Gen Virol. 1993;74(Pt 3):515–8.

47. Damjanovich L, Alfelda SM, Mette SA, Buck CA. Distribution of integrin cell adhesion receptors in normal and malignant lung tissue. Am J Respir Cell Mol Biol. 1992;6:197–206.

48. Mette SA, Pilewski J, Buck CA, Alfelda SM. Distribution of integrin cell adhesion receptors on normal bronchial epithelial cells and lung cancer cells in vitro and in vivo. Am J Respir Cell Mol Biol. 1993;8:562–72.

49. Singh B, Janardhan KS, Ranath R. Expression of angiostatin, integrin alphavbeta3, and vitronectin in human lungs in sepsis. Exp Lung Res. 2005;31:771–82.

50. Burdan T, Wu Y, Perez D, Jett SD, BonduHawkins V, Zeier M, Krautkrämer E. Analysis of the integrin beta3 receptor for pathogenic ortho-hantaviruses in rodent host species. Virus Res. 2019;267:36–40.

51. Tomiani G, Mayor J, Zimmer G, Kunz S, Rothenberger S, Engler O. Macrophage-pinning cytosis contributes to hantavirus entry into human airway epithelial cells. Viruses. 2019;531:57–88.

52. Travany E, Zhou B, Zhang H, Di YP, Alcorn JF, Wentworth DE, Mason R, Wang J. Differential susceptibilities of human lung primary cells to H1N1 influenza viruses. J Virol. 2015;89:1993–44.

53. Kitterer D, Segerer S, Dippon J, Alscher MD, Braun N, Latus J. Smoking is a risk factor for severe acute kidney injury in hantavirus-induced nephropathia epidemica. Nephrol. 2016;134:89–94.

54. Charbonnel N, Pages M, Sirionen T, Henttonen H, Vapalahti O, Mustonen J, Vaheri A. Immunogenetic factors affecting susceptibility of humans and rodents to hantaviruses and the clinical course of hantavirus disease in humans. Viruses. 2014;6:2214–41.

55. Maes P, Clement J, Groeneveld PH, Colson P, Huizinga TW, Van Ranst M. Tumor necrosis factor-alpha genetic predisposing factors can influence clinical severity in nephropathia epidemica. Viral Immunol. 2006;19:558–64.

56. Kanerva M, Vaheri A, Mustonen J, Partanen J. High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe puumala virus-induced nephropathy epidemic. Scand J Infect Dis. 1998;30:532–4.

57. Makela S, Hurme M, Ala-Houhala I, Mustonen J, Koivisto AM, Mustonen J, Vaheri A. Immunogenetic factors affecting susceptibility of humans and rodents to hantaviruses and the clinical course of hantavirus disease in humans. Viruses. 2014;6:2214–41.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.